Clinical Data
The clinical activity of entrectinib has been investigated in adult patients with unresectable or metastatic solid tumours with a NTRK gene fusion in three separate multicentre single-arm, open-label clinical trials (ALKA, STARTRK-1 and STARTRK-2) [1].
Click on the following links to learn more about the currently available efficacy and safety outcomes from these trials.
References
- ROZLYTREK (entrectinib), EMA Summary of medicinal Product Characteristics. 2022.